Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.82 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.73 |
| ▸ | NPC1 | O15118 | 1/20 | 0.72 |
| ▸ | GAA | P10253 | 1/20 | 0.72 |
| ▸ | RAB9A | P51151 | 1/20 | 0.72 |
| ▸ | CNR1 | P21554 | 1/20 | 0.71 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4249871 | 1.00 | MEN1 (0.82) | MEN1KMT2AHSD17B10ALDH1A1SMN1; SMN2 | |
| SCHEMBL4249355 | 0.99 | KMT2A (0.80) | MEN1KMT2AHSD17B10ALDH1A1SMN1; SMN2 | |
| SCHEMBL4251076 | 0.97 | KMT2A (0.77) | MEN1KMT2AHSD17B10ALDH1A1SMN1; SMN2 | |
| SCHEMBL1095479 | 0.90 | KMT2A (1.00) | MEN1KMT2AHSD17B10ALDH1A1SMN1; SMN2 | |
| SCHEMBL1000409 | 0.90 | KMT2A (1.00) | MEN1KMT2AHSD17B10ALDH1A1SMN1; SMN2 | |
| SCHEMBL3646036 | 0.89 | KMT2A (0.66) | MEN1KMT2AHSD17B10ALDH1A1SMN1; SMN2 | |
| SCHEMBL15953291 | 0.85 | TDP1 (0.83) | MEN1KMT2AALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL15825756 | 0.85 | L3MBTL1 (0.89) | MEN1KMT2AALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL1095203 | 0.85 | ALDH1A1 (1.00) | MEN1KMT2AALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL1000557 | 0.85 | ALDH1A1 (1.00) | MEN1KMT2AALDH1A1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104352492-B | Extend enzyme inhibitor using arylsulfonyl derivatives as the long chain fatty acids of active ingredient | MSD K.K.公司 | 2017-12-05 | — | — | CN | disclosed |
| CN-104352492-A | Long-chain fatty acyl elongase inhibitor comprising arylsulfonyl derivative as active ingredient | MSD KK | 2015-02-18 | — | — | CN | disclosed |
| EP-2280001-B1 | LONG-CHAIN FATTY ACID ELONGATION ENZYME INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT | MSD KK (JP) | 2014-10-15 | — | — | EP | disclosed |
| US-8420823-B2 | Long-chain fatty acyl elongase inhibitor comprising arylsulfonyl derivative as active ingredient | MSD K.K. (JP) | 2013-04-16 | — | — | US | disclosed |
| EP-2280001-A1 | LONG-CHAIN FATTY ACID ELONGATION ENZYME INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT | Banyu Pharmaceutical Co., Ltd. (JP) | 2011-02-02 | — | — | EP | disclosed |
| US-20110009622-A1 | LONG-CHAIN FATTY ACYL ELONGASE INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT | MSD K.K. (JP) | 2011-01-13 | — | — | US | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009622-A1 | LONG-CHAIN FATTY ACYL ELONGASE INHIBITOR COMPRISING ARYLSULFONYL DERIVATIVE AS ACTIVE INGREDIENT | ELOVL1, ELOVL6, ELOVL3 | MEN1 4600/4885KMT2A 473/4885HSD17B10 30/4885 |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | GABBR1, GABBR2, CHRM2 | MEN1 1233/4885KMT2A 632/4885HSD17B10 2536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.